June 8, 2020 -- Dutch vaccine developer Intravacc and biotechnology firm Versatope have signed an agreement to collaborate on a universal influenza vaccine.
Intravacc will support Lowell, MA-based Versatope in bringing its universal influenza vaccine candidate VT-105 to clinical trial; the vaccine will include Intravacc's outer membrane vesicles (OMV) technology, the two companies said.
The companies hope that the OMV technology will provide better cross-strain protection than other influenza vaccines that consist of individual strains.